Download PDF
Pädiatrie up2date 2016; 11(04): 315-335
DOI: 10.1055/s-0042-116665
Varia
© Georg Thieme Verlag KG Stuttgart · New York

Psoriasis im Kindes- und Jugendalter

Stefanie Häfliger
,
Nikhil Yawalkar
,
Carolina Gouveia
Further Information

Publication History

Publication Date:
13 December 2016 (online)

Also available at
    Permissions and Reprints All articles of this category

Einleitung

Die Psoriasis ist nach dem atopischen Ekzem die häufigste chronisch-entzündliche Dermatose. Die klinische Präsentation ist, insbesondere bei Manifestation im Kindesalter, mannigfaltig. Da bei Kindern die Symptome milder ausgeprägt sein können und oft weniger typisch sind als bei Erwachsenen, wird die Diagnose häufig spät gestellt. Vor allem die schwere Psoriasis wird heute als Hautmanifestation einer systemischen Entzündungsreaktion mit assoziierten internistischen Komorbiditäten und nicht vernachlässigbaren psychischen Auswirkungen betrachtet. Die Therapie der kindlichen Psoriasis muss, unter anderem wegen altersabhängiger pharmakologischer Besonderheiten, überlegt gewählt werden.

 

  • Literatur

  • 1 Augustin M, Glaeske G, Radtke MA et al. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633-636
    CrossrefGoogle Scholar
  • 2 Swanbeck G, Inerot A, Martinsson T et al. Genetic counselling in psoriasis: empirical data on psoriasis among first-degree relatives of 3095 psoriatic probands. Br J Dermatol 1997; 137: 939-942
    CrossrefGoogle Scholar
  • 3 Bergboer JG, Oostveen AM, de Jager ME et al. Paediatric-onset psoriasis is associated with ERAP1 and IL23R loci, LCE3C_LCE3B deletion and HLA-C*06. Br J Dermatol 2012; 167: 922-925
    CrossrefGoogle Scholar
  • 4 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54
    CrossrefGoogle Scholar
  • 5 Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013; 68: 654-662
    CrossrefGoogle Scholar
  • 6 Gutmark-Little I, Shah KN. Obesity and the metabolic syndrome in pediatric psoriasis. Clin Dermatol 2015; 33: 305-315
    CrossrefGoogle Scholar
  • 7 Kim GE, Seidler E, Kimball AB. Effect of Age at Diagnosis on Chronic Quality of Life and Long-Term Outcomes of Individuals with Psoriasis. Pediatr Dermatol 2015; 32: 656-662
    CrossrefGoogle Scholar
  • 8 Manzoni AP, Weber MB, Nagatomi AR et al. Assessing depression and anxiety in the caregivers of pediatric patients with chronic skin disorders. An Bras Dermatol 2013; 88: 894-899
    CrossrefGoogle Scholar
  • 9 Arakawa A, Siewert K, Stöhr J et al. Melanocyte antigen triggers autoimmunity in human psoriasis. J Exp Med 2015; 212: 2203-2212
    CrossrefGoogle Scholar
  • 10 Valdimarsson H, Thorleifsdottir RH, Sigurdardottir SL et al. Psoriasis – as an autoimmune disease caused by molecular mimicry. Trends Immunol 2009; 30: 494-501
    CrossrefGoogle Scholar
  • 11 Lande R, Botti E, Jandus C et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat Commun 2014; 5: 5621
    CrossrefGoogle Scholar
  • 12 Griffiths CE, Christophers E, Barker JN et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol 2007; 156: 258-262
    CrossrefGoogle Scholar
  • 13 Höger PH, Hamm H. Psoriasis vulgaris bei Kindern und Jugendlichen. Pathogenese, Klinik und Therapie. Hautarzt 2015; 66: 267-276
    CrossrefGoogle Scholar
  • 14 Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther 2004; 17: 364-375
    CrossrefGoogle Scholar
  • 15 Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am 2002; 28: 531-560
    CrossrefGoogle Scholar
  • 16 Marrakchi S, Guigue P, Renshaw BR et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-628
    CrossrefGoogle Scholar
  • 17 Trueb RM. Therapies for Childhood Psoriasis. Curr Probl Dermatol 2009; 38: 137-159
    Google Scholar
  • 18 Ståhle M, Atakan N, Boehncke WH et al. Juvenile psoriasis and its clinical management: a European expert group consensus. J Dtsch Dermatol Ges 2010; 8: 812-818
    Google Scholar
  • 19 Höger P. Kinderdermatologie: Differentialdiagnostik und Therapie bei Kindern und Jugendlichen. 3. Aufl. Stuttgart: Schattauer; 2011: 193,194
    Google Scholar
  • 20 Sticherling M, Augustin M, Boehncke WH et al. Therapy of psoriasis in childhood and adolescence – a German expert consensus. J Dtsch Dermatol Ges 2011; 9: 815-823
    Google Scholar
  • 21 de Jager ME, van de Kerkhof PC, de Jong EM et al. Dithranol therapy in childhood psoriasis: unjustifiably on the verge of falling into oblivion. Dermatology 2010; 220: 329-332
    CrossrefGoogle Scholar
  • 22 Jain VK, Aggarwal K, Jain K et al. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol 2007; 46: 320-322
    CrossrefGoogle Scholar
  • 23 Thorleifsdottir RH, Sigurdardottir SL, Sigurgeirsson B et al. Improvement of psoriasis after tonsillectomy is associated with a decrease in the frequency of circulating T cells that recognize streptococcal determinants and homologous skin determinants. J Immunol 2012; 188: 5160-5165
    CrossrefGoogle Scholar
  • 24 de Jager ME, de Jong EM, van de Kerkhof PC et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. J Am Acad Dermatol 2010; 62: 1013-1030
    CrossrefGoogle Scholar
  • 25 Pereira TM, Vieira AP, Fernandes JC et al. Cyclosporin A treatment in severe childhood psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 651-656
    CrossrefGoogle Scholar
  • 26 Reich K, Hartl C, Gambichler T et al. Retrospective data collection of psoriasis treatment with fumaric acid esters in children and adolescents in Germany (KIDS FUTURE study). J Dtsch Dermatol Ges 2016; 14: 50-58
    Google Scholar
  • 27 Paller AS, Siegfried EC, Pariser DM et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol 2016; 74: 280-287 e1–3
    CrossrefGoogle Scholar
  • 28 Papp K, Gottlieb AB, Naldi L et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Drugs Dermatol 2015; 14: 706-714
    Google Scholar
  • 29 Papp K, Williams D, Thaci D et al. Study design and baseline characteristics from a phase 3, randomized, double-blind study of adalimumab versus methotrexate treatment in pediatric patients with chronic plaque psoriasis. Presented at: 72nd Annual Meeting of the American Academy of Dermatology; March 21–25, 2014. Denver:
    Google Scholar
  • 30 Landells I, Marano C, Hsu MC et al. Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015; 73: 594-603
    CrossrefGoogle Scholar